Schizophrenia Research
Volume 66, Issue 1 , Pages 31-39 , 1 January 2004

Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels

  • Juan Bustillo

      Affiliations

    • Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    • Department of Neurosciences, University of New Mexico Health Sciences Center, Basic Medical Sciences Building, Room 145, Albuquerque, NM 87131, USA
    • Financial support: State of New Mexico Antipsychotic Algorithm Project Consultation Grant from New Mexico Department of Health.
    • Financial support: Mental Illness Neuroscience Discovery Institute.
    • ,
  • Christina Wolff

      Affiliations

    • Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    • ,
  • Adan Myers-y-Gutierrez

      Affiliations

    • Mental Illness Neuroscience Discovery Institute, USA
    • ,
  • Todd S. Dettmer

      Affiliations

    • Department of Neurosciences, University of New Mexico Health Sciences Center, Basic Medical Sciences Building, Room 145, Albuquerque, NM 87131, USA
    • Financial support: UNM-Minority Biomedical Research Support Program funded by NIH Grant R25 GM 60201-2.
    • ,
  • Tom B. Cooper

      Affiliations

    • Nathan Kline Institute, USA
    • College of P&S Columbia University, USA
    • ,
  • Andrea Allan

      Affiliations

    • Department of Neurosciences, University of New Mexico Health Sciences Center, Basic Medical Sciences Building, Room 145, Albuquerque, NM 87131, USA
    • ,
  • John Lauriello

      Affiliations

    • Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    • Financial support: State of New Mexico Antipsychotic Algorithm Project Consultation Grant from New Mexico Department of Health.
    • ,
  • C.Fernando Valenzuela

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-505-272-3128; fax: +1-505-272-8082.
    • Department of Neurosciences, University of New Mexico Health Sciences Center, Basic Medical Sciences Building, Room 145, Albuquerque, NM 87131, USA
    • Financial support: NIH Grants MH63126 and AA12684.

Received 6 June 2002 ,Revised 2 December 2002 ,Accepted 12 December 2002.

References 

  1. Adalsteinsson E, Sullivan EV, Kleinhans N, Speilman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000;355:1696–1697
  2. Baldessarini RJ, Hegarty JD, Bird ED, Benes FM. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am. J. Psychiatry. 1997;154:861–863
  3. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1997;54(10):959–965
  4. Bartha R, al-Semaan YM, Williamson PC, Drost DJ, Malla AK, Carr TJ, et al. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry. 1999;45:1403–1411
  5. Bartlett E, Brodie J, Simkowitz P, Dewey S, Rusinek H, Wolf A, et al  Effects of haloperidol challenge on regional cerebral glucose utilization in normal subjects. Am. J. Psychiatry. 1994;151:681–686
  6. Baslow MH. Functions of N-acetyl-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in glial cell specific signaling. J. Neurochem. 2000;75:453–459
  7. Benes F, Paskevich P, Davidson J, Domesick V. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res. 1985;329:265–274
  8. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopy imaging. Am. J. Psychiatry. 1996;153:1554–1563
  9. Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA, et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am. J. Psychiatry. 2000;157:26–33
  10. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry. 2001;49:39–46
  11. Bhakoo KK, Pearce D. In vitro expression of N-acetyl-aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J. Neurochem. 2000;74:254–262
  12. Bianchetti G, Moselli PL. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen–phosphorus selective detection. J. Chromatogr. 1978;153:203–209
  13. Braus D, Ende G, Weber-Fahr W, Demirakca T, Henn F. Favorable effect on neuronal viability in the anterior cingulated gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry. 2001;34:251–253
  14. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA. Functioning and neuronal viability of the anterior cingulated neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 2002;12:145–152
  15. Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J. Rheumatol. 1999;26:81–85
  16. Buckley PF, Moore C, Long H, Larkin C, Thompson P, Mulvany F, et al. 1H-Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry. 1994;36:792–800
  17. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, et al. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. Neuroimaging. 2001;107(3):135–149
  18. Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulos H, Hammond R, et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002;58:313–321
  19. Cecil KM, Lenkinski RE, Gur RE, Gu RC. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naı̈ve patients with schizophrenia. Neuropsychopharmacology. 1999;20:131–140
  20. Chakos M, Lieberman J, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 1995;345:456–457
  21. Choe BY, Ki-Tae K, Suh TS, Lee CW, Lee C, Paik IH, et al. H-magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naı̈ve, chronic schizophrenia. Acad. Radiol. 1994;1:211–216
  22. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 1996;6:345–352
  23. Daughtry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 2000;20:289–299
  24. Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry. 1997;154:688–690
  25. Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol. Psychiatry. 1998;43:483–488
  26. Deicken RF, Johnson C, Eliaz Y, Schuff N. Reduced concentrations of thalamic N-acetylaspartate in males patients with schizophrenia. Am. J. Psychiatry. 2000;157(4):644–647
  27. Deicken RF, Feiwell R, Schuff N, Soher B. Evidence for altered cerebellar vermis integrity in schizophrenia. Psychiatry Res. 2001;107:125–134
  28. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. Neuroimaging. 1997;74:129–140
  29. Eluri R, Paul C, Roemer R, Boyko O. Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study. Psychiatry Res. Neuroimaging. 1998;84:17–26
  30. Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA, et al. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 2000;41:389–395
  31. Florian C, Williams S, Bhakoo K, Noble M. Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using H-NMR spectroscopy and high performance liquid chromatography. Neurochem. Res. 1996;21:1065–1074
  32. Friedman SD, Stidley CA, Brooks WM, Hart BL, Sibbitt WL. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology. 1998;209:79–84
  33. Fukuzako H, Takeuchi K, Hokazono Y, Fukuzako T, Yamada K, Hashiguchi T, et al. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. Neuroimaging. 1995;61:193–200
  34. Giedd JN, Jeffries NO, Blumenthal J, Castellanos FX, Vaituzis AC, Fernandez T, et al. Childhood-onset schizophrenia: progressive brain changes during adolescence. Biol. Psychiatry. 1999;46(7):892–898
  35. Gur RE, Cowell P, Turetsky BI, Gallaghe F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Arch. Gen. Psychiatry. 1998;55:145–152
  36. Harrison P. The neuropathological effects of antipsychotic drugs. Schizophr. Res. 1999;40:87–99
  37. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. Neuroimaging. 1998;83:105–115
  38. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry. 1996;153:41–49
  39. Jung RE, Brooks WM, Yeo RA, Chiulli SJ, Weers DC, Sibbitt WL. Biochemical markers of intelligence: a proton MR spectroscopy study of normal human brain. Proc. R. Soc. Lond., B. 1999;226:1375–1379
  40. Kegeles LS, Shungu DC, Anjilvel S, Chan S, Ellis SP, Xanthopoulos E, et al. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. Neuroimaging. 2000;98:163–175
  41. Kelley J, Gao X, Tamminga C, Roberts R. The effects of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp. Neurol. 1997;146:471–478
  42. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment (letter). Lancet. 1994;344:1434
  43. Kikuchi S, Kubota F, Hattori S, Oya N, Mikuni M. A study of the relationship between metabolism using 1H-MRS and function using several neuropsychological tests in temporal lobe epilepsy. Seizure. 2001;10:188–193
  44. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J. Neurochem. 1984;43(4):1136–1142
  45. Lidow M, Goldman-Rakic P. A common action of clozapine, haloperidol and remoxepride on D1 and D2 dopamine receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 1994;91:4353–4356
  46. Lidow M, Zan-Min S, Castner S, Allen P, Greengard P, Goldman-Rakic P. Antipsychotic treatment induces alterations in dendrite and spine associated proteins in dopamine rich areas of the primate cerebral cortex. Biol. Psychiatry. 2001;49:1–12
  47. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry. 2001;49:487–499
  48. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pferfferbaum A. Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry. 1998;55:346–352
  49. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn. Reson. Med. 2000;43:355–358
  50. Lopez-Villegas D, Lenkinski RE, Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 1997;94:9854–9859
  51. Maier M, Ron MA, Barker GJ, Tofts PS. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 1995;25:1201–1209
  52. Martin RC, Sawrie S, Hugg J, Gilliam F, Faught E, Kuzniecky R. Cognitive correlates of 1H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy. Neurology. 1999;53:2052–2058
  53. Meshul C, Bunker G, Mason J, Allen C, Janowsky A. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 1996;67:1965–1973
  54. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol. Psychiatry. 2001;49(8):704–715
  55. Moffet JR, Namdoori MAA. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 1995;24:409–433
  56. Nasrallah HA, Skinner TE, Schmalbrock P, Robitaille PM. Proton magnetic resonance spectroscopy (1H-MRS) of the hippocampal formation in schizophrenia: a pilot study. Br. J. Psychiatry. 1994;165:481–485
  57. Nielsen B, Lyon M. Evidence for cell loss in corpus stratum after long-term treatment with neuroleptic drug (flupentixol) in rats. Pharmacology. 1978;59:85–89
  58. Omori M, Murata T, Kimura H, Koshimoto Y, Kado H, Ishimori Y, et al. Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res. Neuroimaging. 2000;98:155–162
  59. Palao D, Arauxo A, Brunet M, Bernardo M, Haro J, Ferrer J, et al. Haloperidol: therapeutic window in schizophrenia. J. Clin. Psychopharmacol. 1994;14:303–310
  60. Pauli E, Eberhardt KW, Schafer I, Tomand B, Huk WJ, Stefan H. Chemical shift imaging spectroscopy and memory function in temporal lobe epilepsy. Epilepsia. 2000;41:282–289
  61. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 1999;41(2):276–284
  62. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am. J. Psychiatry. 1995;152(3):444–446
  63. Roberts R, Gaither L, Gao X, Kashyap S, Tamminga C. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse. 1995;20:234–243
  64. Ross BD, Ernst T, Kreis R, Haseler LJ, Bayer S, Danielsen E, et al. 1H MRS in acute traumatic brain injury. J. Magn. Reson. Imaging. 1998;8:829–840
  65. Rowland L, Bustillo J, Lauriello J. Proton magnetic resonance spectroscopy (1H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry. 2001;6:121–130
  66. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol. Psychiatry. 1999;46:161–172
  67. Simpson G, Cooper T. Clozapine plasma level and convulsions. Am. J. Psychiatry. 1978;135:99–100
  68. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 1996;22(4):597–609
  69. Taylor DL, Davies SE, Obrenovitch TP, Urenjak J, Richards DA, Clarck JB, et al. Extracellular N-acetyl-aspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J. Neurochem. 1994;62:2349–2355
  70. Thomas MA, Ke Y, Levitt J, Caplan R, Curran J, Asarnow R, et al. Preliminary study of frontal lobe 1HMR spectroscopy in childhood-onset schizophrenia. J. Magn. Reson. Imaging. 1998;8:841–846
  71. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 1995;46(5):531–540
  72. VanderZwaag C, McGee M, McEvoy J, Freudenreich O, Wilson W, Cooper T. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J. Psychiatry. 1996;153:1579–1584
  73. Williamson P, Theberge J, Bartha R, Drost D, Malla A, Densmore M, et al. Glutamate, glutamine and N-acetylaspartate in the anterior cingulate and thalamus of never-treated schizophrenic patients with 4.0 tesla 1H MRS. Schizophr. Res. 2001;49:196
  74. Yurgelun-Todd DA, Renshaw PF, Gruber SA, Ed M, Waternaux C, Cohen BM. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr. Res. 1996;19:55–59

PII: S0920-9964(02)00528-5

doi: 10.1016/S0920-9964(02)00528-5

Schizophrenia Research
Volume 66, Issue 1 , Pages 31-39 , 1 January 2004

Article Tools

* Image Usage & Resolution